2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. Olinvacimab

Olinvacimab  (Synonyms: TTAC-0001)

Cat. No.: HY-P99768 Purity: ≥95.0%
Data Sheet
SDS
COA
Technical Support

Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.

For research use only. We do not sell to patients.

CAS No. : 2095504-49-5

Size Price Stock Quantity
1 mg USD 260 In-stock
5 mg USD 680 In-stock
10 mg USD 1080 In-stock
50 mg   Get quote  
100 mg   Get quote  

Get it by June 3 for select sizes. Order within 21 hrs 9 mins.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Olinvacimab Featured Recommendations:

Top Publications Citing Use of Products

View All VEGFR Isoform Specific Products:

View All Isoforms
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer[1].

Isotype

Human IgG1 kappa
Species

Humanized
In Vitro

Olinvacimab (0-1000 nM) inhibits binding of VEGF to its receptor KDR with a Kd value of 0.23 nM[1].
Olinvacimab inhibits VEGF-165, VEGF-C and VEGF-D binding to VEGFR-2 with IC50 values of 8.7, 6.3 and 7.0 nM, respectively[1].
Olinvacimab (0.5-30 μg/mL; 30 min) inhibits the phosphorylation of VEGFR-2/KDR and ERK[1].
Olinvacimab (1, 15 and 20 mg/mL; 30 min) inhibits VEGF-induced proliferation of HUVEC[1].
Olinvacimab (20 mg/mL; 30 min) inhibits VEGF-stimulated HUVEC migration[1].
Olinvacimab (5, 10 and 20 μg; 20 h) dose-dependently inhibits tube formation and disorders tubular structures[1].
Olinvacimab (1 and 20 μg; 6 d) inhibits hVEGF165-induced rat aortic ring vessel sprouting[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: Human umbilical vein endothelial cell (HUVEC) line
Concentration: 0.5, 1, 5, 10, 20 and 30 μg/mL
Incubation Time: 30 min
Result: Inhibited VEGF-induced phosphorylation of VEGFR-2 and ERK (downstream signaling molecule) in HUVECs.
In Vivo

Olinvacimab (100 ng; s.c., once) inhibits angiogenesis in vivo[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Matrigel-implanted nude mice model[1]
Dosage: 100 ng
Administration: Subcutaneous injection; 100 ng, once
Result: Inhibited the neovascularization induced by hVEGF165.
Clinical Trial
Molecular Weight

148.16 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Olinvacimab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • IgG1-Vlambda-Ckappa
Purity & Documentation

Purity: ≥95.0%

Data Sheet (259 KB) SDS (251 KB)

COA (232 KB)

Inhibitory Antibodies User Guide (602 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Olinvacimab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Olinvacimab2095504-49-5TTAC-0001TTAC0001TTAC 0001VEGFRVascular endothelial growth factor receptorphosphorylationERKHUVECmigrationtube formationantiangiogenicInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Olinvacimab
Cat. No.:
HY-P99768
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.